Product Description
Icodextrin (Extraneal) is a high molecular weight glucose polymer developed specifically for use as an alternative osmotic agent to dextrose during the once-daily long-dwell exchange in peritoneal dialysis (PD) (Sourced from: https://pubmed.ncbi.nlm.nih.gov/12962523/)
Mechanisms of Action: ADRA2A Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Baxter Healthcare
Company Location: DEERFIELD IL 60015
Company CEO: José E. Almeida
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Mexico
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Heart Failure
Phase 1: Kidney Failure, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PURE | P2 |
Active, not recruiting |
Heart Failure |
2024-11-16 |
|
| R-2022-785-034 | P1 |
Recruiting |
Kidney Failure, Chronic |
2023-08-30 |